AIMS: Syncope can lead to injuries. We determined the frequency, severity, and predictors of injuries due to syncope in cohorts of syncope patients. METHODS AND RESULTS: Participants were enrolled in the POST2 (fludrocortisone) and POST4 (midodrine) vasovagal syncope (VVS) randomized trials, and POST3 enrolled patients with bifascicular block and syncope. Injury was defined as minor (bruising, abrasions), moderate (lacerations), and severe (fractures, burns, joint pain), and recorded up to 1 year after enrolment. A total of 459 patients (median 39 years) were analysed. There were 710 faints occurred in 186 patients during a 1-year follow-up. Fully 56/186 (30%) of patients were injured with syncope (12% of overall group). There were 102 injuries associated with the 710 faints (14%), of which 19% were moderate or severe injuries. Neither patient age, sex, nor the presence of prodromal symptoms associated with injury-free survival. Patients with bifascicular block were more prone to injury (relative risk 1.98, P = 0.018). Patients with ≥4 faints in the prior year had more injuries than those with fewer faints (relative risk 2.97, P < 0.0001), but this was due to more frequent syncope, and not more injuries per faint. In VVS patients, pharmacological therapy significantly reduced the likelihood of an injury due to a syncopal spell (relative risk 0.64, P = 0.015). Injury severity did not associate with age, sex, or prior-year syncope frequency. CONCLUSION: Injuries are frequent in syncope patients, but only 4% of injuries were severe. None of age, sex, and prodromal symptoms associate with injury. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Syncope can lead to injuries. We determined the frequency, severity, and predictors of injuries due to syncope in cohorts of syncopepatients. METHODS AND RESULTS:Participants were enrolled in the POST2 (fludrocortisone) and POST4 (midodrine) vasovagal syncope (VVS) randomized trials, and POST3 enrolled patients with bifascicular block and syncope. Injury was defined as minor (bruising, abrasions), moderate (lacerations), and severe (fractures, burns, joint pain), and recorded up to 1 year after enrolment. A total of 459 patients (median 39 years) were analysed. There were 710 faints occurred in 186 patients during a 1-year follow-up. Fully 56/186 (30%) of patients were injured with syncope (12% of overall group). There were 102 injuries associated with the 710 faints (14%), of which 19% were moderate or severe injuries. Neither patient age, sex, nor the presence of prodromal symptoms associated with injury-free survival. Patients with bifascicular block were more prone to injury (relative risk 1.98, P = 0.018). Patients with ≥4 faints in the prior year had more injuries than those with fewer faints (relative risk 2.97, P < 0.0001), but this was due to more frequent syncope, and not more injuries per faint. In VVS patients, pharmacological therapy significantly reduced the likelihood of an injury due to a syncopal spell (relative risk 0.64, P = 0.015). Injury severity did not associate with age, sex, or prior-year syncope frequency. CONCLUSION: Injuries are frequent in syncopepatients, but only 4% of injuries were severe. None of age, sex, and prodromal symptoms associate with injury. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Andrew D Krahn; Carlos A Morillo; Teresa Kus; Braden Manns; Sarah Rose; Michele Brignole; Robert S Sheldon Journal: Europace Date: 2012-02-08 Impact factor: 5.214
Authors: Robert Sheldon; Stuart Connolly; Sarah Rose; Thomas Klingenheben; Andrew Krahn; Carlos Morillo; Mario Talajic; Teresa Ku; Fetnat Fouad-Tarazi; Debbie Ritchie; Mary-Lou Koshman Journal: Circulation Date: 2006-02-27 Impact factor: 29.690
Authors: Gonzalo Barón-Esquivias; Silvia Gómez; Almudena Aguilera; Ana Campos; Nieves Romero; Aurelio Cayuela; Juan I Valle; Mercedes Redondo; Alonso Pedrote; José Burgos; Angel Martínez; Francisco Errázquin Journal: Int J Cardiol Date: 2005-07-10 Impact factor: 4.164
Authors: Robert Sheldon; Satish R Raj; M Sarah Rose; Carlos A Morillo; Andrew D Krahn; Eduardo Medina; Mario Talajic; Teresa Kus; Colette M Seifer; Malgorzata Lelonek; Thomas Klingenheben; Ratika Parkash; Debbie Ritchie; Maureen McRae Journal: J Am Coll Cardiol Date: 2016-07-05 Impact factor: 24.094
Authors: Anna-Karin Numé; Nicolas Carlson; Thomas A Gerds; Ellen Holm; Jannik Pallisgaard; Kathrine B Søndergaard; Morten L Hansen; Michael Vinther; Jim Hansen; Gunnar Gislason; Christian Torp-Pedersen; Martin H Ruwald Journal: PLoS One Date: 2018-11-21 Impact factor: 3.240
Authors: Artur Fedorowski; Mirnabi Pirouzifard; Jan Sundquist; Kristina Sundquist; Richard Sutton; Bengt Zöller Journal: JAMA Netw Open Date: 2021-03-01
Authors: Nicola Magnavita; Reparata Rosa Di Prinzio; Gabriele Arnesano; Anna Cerrina; Maddalena Gabriele; Sergio Garbarino; Martina Gasbarri; Angela Iuliano; Marcella Labella; Carmela Matera; Igor Mauro; Franca Barbic Journal: Int J Environ Res Public Health Date: 2021-11-23 Impact factor: 3.390